Overview

This trial is active, not recruiting.

Condition congestive heart failure
Treatments myocell, hypothermosol
Phase phase 2/phase 3
Sponsor Bioheart, Inc.
Start date September 2007
End date February 2017
Trial size 170 participants
Trial identifier NCT00526253, BMI-WW-02-003

Summary

This study injects a person's own stem cells into heart muscle tissue after a person has one or more heart attacks. The purpose of the study is whether the stem cells will improve a patient's heart performance.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator)
Primary purpose treatment
Arm
(Active Comparator)
Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
myocell
Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 400 million cells.
(Active Comparator)
Patient will undergo biopsy. Skeletal myoblasts will be cultured in growth media.
myocell
Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 800 million cells.
(Placebo Comparator)
Patient will undergo biopsy of muscle tissue and biopsy tissue will be sent to lab.
hypothermosol
After the cell culture period of time has passed, patient's myocardium will be injected with the transport media alone. Patient will not receive any cultured myoblasts during these injections.

Primary Outcomes

Measure
6-minute walk test
time frame: 6 months
Quality of Life Questionnaire
time frame: 6 months

Secondary Outcomes

Measure
Hospitalization occurrences
time frame: 12 months

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: Eligible patients must meet ALL of the following inclusion criteria during the screening/enrollment visit #1 and prior to being randomized into the study. Screening/enrollment visit #1 is defined to start the date the ICF is signed by the patient: 1. Chronic CHF, New York Heart Association (NYHA) Class II-IV; 2. Stable and on optimal medical management for greater or equal to 60 days as follows: 1. systolic and diastolic hypertension controlled in accordance with contemporary guidelines; 2. patient stabilized on maximum tolerated dose of beta blockers; 3. patient stabilized on maximum tolerated dose of angiotensin concerting enzyme (ACE) inhibitors; 4. patients intolerant of ACE inhibitors should be stabilized on angiotensin receptor blockers (ARB); 5. fluid control with diuretics and a salt restricted diet; 6. patients with sever symptoms of heart failure (Class III-IV) lacking contraindications to aldosterone antagonism and not on both ACE inhibitors and ARBs have been considered for such therapy. 3. Age 18-80; 4. Left ventricular ejection fraction (LVEF) at screening of less than or equal to 35 percent by multiple gaited acquisition scan (MUGA); 5. Need or feasibility for revascularization has been ruled out by previous coronary angiogram or ruled out to the satisfaction of the investigator via previous conventional stress study completed within 1 year of screening. The need or feasibility for revascularization will be reassessed at screening using dobutamine stress echocardiography (DSE); 6. Defined region of mycardial dysfunction related to previous MI involving the anterior, later, posterior or inferior walls including the apical septum (excluding the basal septum) assessed by a large area of akinesia in the left ventricle (using DSE at screening); 7. B-type natriuretic peptide (BNP) or NT pro-BNP is above the upper limit of normal. Exclusion Criteria: 1. Non-pregnant women who are not postmenopausal, surgically sterile or not practicing an acceptable method of contraception. A female patient of child bearing potential, with a positive serum or urine pregnancy test at screening visit #1. Females refusing to exercise a reliable form of contraception; 2. Myocardial wall thickness of <6 mm (millimeters) in the akinetic myocardial region to be injected (using DSE at screening) 3. Inability to undergo a surgical biopsy of the skeletal muscle for culture of myoblasts, including any significant myopathy; 4. Patient will require revascularization within six months; 5. Patients on continuous or intermittent intravenous drug therapy; 6. Not fitted, or fitted within less than 90 days prior to screening visit #1, with an implantable cardioverter defibrillator (ICD); 7. Sustained ventricular tachycardia (VT), automatic implantable cardiodefibrillator (AICD) firing, or ventricular fibrillation (VF) within 90 days prior to screening visit #1; 8. Inability to perform a 6 minute walk test due to physical limitations other than HF including: 1. Severe peripheral vascular disease, including aortic aneurysms, leading to limited claudication; 2. Severe pulmonary disease or chronic obstructive pulmonary disease (COPD) limiting exercise, dependence on chronic oral steroid therapy or previously requiring mechanical ventilation; 3. Stroke or transient ischemic attack leading to limitations in lower extremities or occurring within 180 days prior to screening visit #1; 9. MI, unstable angina or percutaneous coronary intervention (PCI) within 90 days prior to screening; 10. having undergone CABG surgery within 150 days prior to screening visit #1; 11. Active myocarditis, constrictive pericarditis, restrictive, hypertrophic or congenital cardiomyopathy; 12. Hemodynamically significant severe primary valvular heart disease, unless corrected by a properly functional prosthetic valve; 13. Prior aortic valve replacement; 14. Systolic blood pressure (supine) ≤90 mmHg; 15. Resting heart rate >100 bpm; 16. Severe uncontrolled HF including any evidence of severe fluid overload such as peripheral edema >+2 or rales ≥1/3 the lungs' height, need for intravenous therapy for HF within 60 days of screening visit #1 or hospitalization for HF within 90 days of screening visit #1; 17. Patient scheduled to receive cardiac resynchronization therapy (CRT) during the study; 18. Expected to receive or received a cardiac transplant, surgical remodeling procedure, left ventricular assist device or cardiomyoplasty; 19. Six-minute walk test (6MWT) of >400 meters or Minnesota Living With Heart Failure (MLWHF) score of <20; 20. Hematocrit (HCT) concentration below 30% (males) or below 27% (females); 21. Serum creatinine greater than 2.5 mg/dL (milligrams per deciliter) or end stage renal disease; 22. Left ventricular mural thrombus; 23. Known sensitivity to gentamicin sulfate; or severe adverse reaction to nonionic radiocontrast agents; 24. Active infectious disease and/or known to have tested positive for human immunodeficiency virus (HIV), human t lymphotrophic virus (HTLV), hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV); immunoglobulin M [IgM], and/or syphilis. If the panel includes antibodies to the HBV core antigen (HBV-cAg) and hepatitis B surface antigen (HBV-sAg), then an expert will be consulted as to patient's eligibility based on the patient's infectious status; 25. Patients have undergone enhanced external pulsation (EECP) tratment within the last 6 months; 26. Exposure to any previous experimental angiogenic therapy and/or myocardial laser therapy, or therapy with another investigational drug within 60 days of screening visit #1 or enrollment in any concurrent study that may confound the results of this study; 27. Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or in the opinion of the investigator are not suitable to participate; 28. Any illness other than CHF which might reduce life expectancy to less than 1 year from screening visit #1; 29. Recent initiation of cardiac resynchronization therapy via placement of a bi-ventricular pacemaker or bi-ventricular AICD within 180 days of study enrollment; and 30 Unwilling and/or not able to give written informed consent.

Additional Information

Official title A Multicenter Study to Assess the Safety and Cardiovascular Effects of Myocell™ Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post Myocardial Infarction(s)
Description Autologous myoblasts are harvested from a patient's skeletal muscle tissue. The myoblasts are isolated and expanded in culture in a closed system. When a sufficient number of cells are estimated they are taken from culture, packaged in a suspension and sent to the patient's interventionalist. The interventionalist uses an injection catheter via femoral artery to inject the myoblasts directly into the myocardium.
Trial information was received from ClinicalTrials.gov and was last updated in January 2015.
Information provided to ClinicalTrials.gov by Bioheart, Inc..